Withaferin A synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancer
- PMID: 22860102
- PMCID: PMC3408484
- DOI: 10.1371/journal.pone.0042265
Withaferin A synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancer
Abstract
Application of doxorubicin (Dox) for the treatment of cancer is restricted due to its severe side effects. We used combination strategy by combining doxorubicin (Dox) with withaferin A (WFA) to minimize the ill effects of Dox. Treatment of various epithelial ovarian cancer cell lines (A2780, A2780/CP70 and CaOV3) with combination of WFA and Dox (WFA/DOX) showed a time- and dose-dependent synergistic effect on inhibition of cell proliferation and induction of cell death, thus reducing the dosage requirement of Dox. Combination treatment resulted in a significant enhancement of ROS production resulting in immense DNA damage, induction of autophagy analyzed by transmission electron microscope and increase in expression of autophagy marker LC3B, and culminated in cell death analyzed by cleaved caspase 3. We validated combination therapy on tumor growth using an in vitro 3Dimension (3D) tumor model and the more classic in vivo xenograft model of ovarian cancer. Both tumor models showed a 70 to 80% reduction in tumor growth compared to control or animals treated with WFA or Dox alone. Immunohistochemical analysis of the tumor tissues from animals treated with WFA/Dox combination showed a significant reduction in cell proliferation and formation of microvessels accompanied by increased in LC3B level, cleaved caspase 3, and DNA damage. Taken together, our data suggest that combining WFA with Dox decreases the dosage requirement of Dox, therefore, minimizing/eliminating the severe side effects associated with high doses of DOX, suggesting the application of this combination strategy for the treatment of ovarian and other cancers with no or minimum side effects.
Conflict of interest statement
Figures











Similar articles
-
Synergistic cytotoxic action of cisplatin and withaferin A on ovarian cancer cell lines.Biochem Biophys Res Commun. 2012 Jul 13;423(4):819-25. doi: 10.1016/j.bbrc.2012.06.047. Epub 2012 Jun 16. Biochem Biophys Res Commun. 2012. PMID: 22713472 Free PMC article.
-
Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma Cells.Int J Mol Sci. 2017 May 12;18(5):1048. doi: 10.3390/ijms18051048. Int J Mol Sci. 2017. PMID: 28498322 Free PMC article.
-
DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer.J Cancer Stem Cell Res. 2016;4:e1002. doi: 10.14343/JCSCR.2016.4e1002. Epub 2016 Apr 19. J Cancer Stem Cell Res. 2016. PMID: 27668267 Free PMC article.
-
Theanine and glutamate transporter inhibitors enhance the antitumor efficacy of chemotherapeutic agents.Biochim Biophys Acta. 2003 Dec 5;1653(2):47-59. doi: 10.1016/s0304-419x(03)00031-3. Biochim Biophys Acta. 2003. PMID: 14643924 Review.
-
Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity.Cells. 2023 Feb 19;12(4):659. doi: 10.3390/cells12040659. Cells. 2023. PMID: 36831326 Free PMC article. Review.
Cited by
-
Withaferin a alone and in combination with cisplatin suppresses growth and metastasis of ovarian cancer by targeting putative cancer stem cells.PLoS One. 2014 Sep 29;9(9):e107596. doi: 10.1371/journal.pone.0107596. eCollection 2014. PLoS One. 2014. PMID: 25264898 Free PMC article.
-
Resveratrol protects PC12 cells against OGD/ R-induced apoptosis via the mitochondrial-mediated signaling pathway.Acta Biochim Biophys Sin (Shanghai). 2016 Apr;48(4):342-53. doi: 10.1093/abbs/gmw011. Acta Biochim Biophys Sin (Shanghai). 2016. PMID: 26960953 Free PMC article.
-
The Therapeutic Effects of Withaferin A against Cancer: Overview and Updates.Curr Mol Med. 2024;24(4):404-418. doi: 10.2174/1566524023666230418094708. Curr Mol Med. 2024. PMID: 37076466 Review.
-
Withaferin A as a Potential Therapeutic Target for the Treatment of Angiotensin II-Induced Cardiac Cachexia.Cells. 2024 May 3;13(9):783. doi: 10.3390/cells13090783. Cells. 2024. PMID: 38727319 Free PMC article.
-
Anti-cancer activity of withaferin A in B-cell lymphoma.Cancer Biol Ther. 2015;16(7):1088-98. doi: 10.1080/15384047.2015.1046651. Cancer Biol Ther. 2015. PMID: 26020511 Free PMC article.
References
-
- Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10–29. - PubMed
-
- Pfisterer J, Ledermann JA (2006) Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol 33: S12–16. - PubMed
-
- Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N (2000) Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem 207: 77–86. - PubMed
-
- Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, et al. (2009) Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 16: 3267–3285. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials